Replies to post #197888 on Biotech Values

[DewDiligence]

ABBV/ENTA—I partly agree: qD dosing is a non-trivial convenience benefit for V-Pak patients who don’t need ribavirin—i.e. GT1b patients without cirrhosis. OTOH, for patients who do need ribavirin, it probably doesn’t make much difference whether V-Pak’s Dasabuvir component is dosed qD or BID.